| |
 |
 |
| |
| Kollodis provides a one-stop solution to all our customer's needs. |
| |
| We provide highly specific biochemical microenvironments that mimic in vivo like environments by tailoring an extracellular matrix (ECM) for cell therapy or tissue engineering scaffolding. Our customized MAPTrixTM services include: |
|
| ● Thiolation of mussel adhesive protein by incorporating cystein residues into N- or C- terminal of a mussel adhesive protein for three dimensional extracellular matrix such as hydrogel or nanofiber |
| ● Peptide design and recombinant incorporation at N-, C- or both N- and C-terminal of a mussel adhesive protein for specific biofunctionality or density control of bioligands |
| |
| Our manufacturing facilities are ISO compliant for optimal quality control. We provide the highest quality control in the implementation of our proprietary MAPTrix™ Technology. |
| |
| Customized Services that Commercialize Your Unique Peptide
|
| Do you have a great peptide that you would like to share with your colleagues and others as well as make some additional money? Our technology licensing procedures are simple and flexible and often provide researchers with additional monetary income. |
| |
| Working Process
|
 |
| |
| Service Description |
| Service Type |
Service Description |
Time |
Basic Cost |
| Standard
Service |
- Protein amount: 200 mg
- Quality
1) Sequence identity
2) Purity : 90% > by SDS
3) Endotoxin : Less than 20 EU/ml
4) Sterilized
|
4 weeks |
- US$ 3,000
- Extra charge may be applicable, depending on the length or nature of peptide
- Ask us for details |
| Special
Service |
- Bulk production service (gram scale)
- Bifunctional mussel adhesive protein
* peptide motif at both N- and C
- terminal |
- |
- Ask us for details |
|
| |
We can not provide our tailored service for peptide that may violate
third party intellectual property or patent rights |
| |
| |
| The function and bioactivity of your peptide of interest can be search online at PepBank |
| |
|
 |
Available Peptide Sequence for Your Cell Study
|
| F1 Domain |
Gly-Arg-Gly-Asp-Ser (GRGDS) |
| |
| F2 Domain |
Gly-Gly-Trp-Ser-His-Trp (GGWSHW)
Gly-Gly-Trp-Ser-Lys-Trp (GGWSKW)
Trp-Ser-His-Trp-Ser-Pro (WSHWSP) |
| |
| F3 Domain |
His-Asp-Val-Leu-Lys (HDVLK)
Arg-Ala-Ala-Val (RAAV)
Gln-Ala-Gln-Gln (QAQQ) |
| |
※ References:
1. J. Biol. Chem., 1989, 264(26), 15165-8
2. J. Cell Biol., 1993, 121(2), 469-77
3. US 5679320, US 5491130 |
| |
| |
|
 |
| |
Available Peptide Sequence for Your Cell Study |
| |
| F1 Domain |
Lys-Gln-Asn-Cys-Leu-Ser-Ser-Arg-Ala-Ser-Phe-Arg-Gly-Cys-Val-Arg-Asn-Leu-Arg-Leu-Ser-Arg
(KQNCLSSRASFRGCVRNLRLSR) |
| |
| F2 Domain |
Lys-Leu-Val-Glu-His-Val-Pro-Gly-Arg-Pro-Val-Arg-His-Ala-Gln-Cys-Arg
(KLVEHVPGRPVRHAQCR)
Arg-Pro-Val-Arg-His-Ala-Gln-Cys-Arg-Val-Cys-Asp-Gly-Asn-Ser-Thr-Asn-Pro-Arg-Glu-Arg-His
(RPVRHAQCRVCDGNSTNPRERH) |
| |
| F3 Domain |
AArg-Tyr-Val-Val-Leu-Pro-Arg-Pro-Val-Cys-Phe-Glu-Lys-Gly-Met-Asn-Tyr-Thr-Val-Arg ?
(RYVVLPRPVCFEKGMNYTVR) |
※ References:
1. J. Invest. Dermatol., 1991, 97, 141-146
2. J. Cell Biol., 1994, 124(6), 1083-1090
3. J. Cell Biol., 1988, 107, 1253-1260
4. US 5276136
|
| |
| |
|
 |
| Currently available peptide motif for tailored mussel adhesive for building blocks for ECM
|
The following tailored service cannot be available for the customer in the United States due to patent violation issue. |
| |
| F1 Domain |
Gly-Lys-Arg-Gly-Ala-Arg-Gly-Glu-Pro-Gly-Pro-Ala (GKRGARGEPGPA)
Gly-Ala-Pro-Gly-Asp-Lys-Gly-Leu-Arg-Gly-Leu-Thr (GAPGDKGLRGLT) |
| |
| F2 Domain |
Pro-Arg-Ala-Arg-Ile-Tyr (PRARIY)
Arg-Ala-Arg-Ile-Tyr (RARIY)
Ala-Arg-Ile-Tyr (ARIY) |
| |
※ References:
1. US 5731409 |
| |
| |
|
 |
| Currently available peptide motif for tailored mussel adhesive for building blocks for ECM |
| |
| F1 Domain |
Leu-Ala-Gly-Ser-Cys-Leu-Ala-Arg-Phe-Ser-Thr-Met (LAGSCLARFSTM)
Asn-Pro-Leu-Cys-Pro-Pro-Gly-Thr-Lys-Ile-Leu (NPLCPPGTKIL)
Thr-Ala-Gly-Ser-Cys-Leu-Arg-Lys-Phe-Ser-Thr-Met (TAGSCLRKFSTM) |
※ References:
1. J. Biol. Chem., 1989, 264(4), 2313-2323
2. J. Cell Biol., 1990, 111, 1583-1591
3. US 5081031, US 5059425
|
| |
| |
 |